title: Rosuvastatin inhibits TGF-beta1 expression and alleviates myocardial fibrosis in diabetic rats.
abstract: This study aimed to investigate the effects of rosuvastatin on TGF-beta1 expression, cardiac fibrosis, ventricular remodeling and cardiac function in diabetic cardiomyopathy rats. Twenty-seven diabetic rats induced by streptozotocin intraperitoneal injection were randomly divided into three groups, viz. diabetic, rosuvastatin low-dose (Ros-L) and high dose group (Ros-H). Intervention group were given rosuvastatin 2 mg/kg/d and 5 mg/kg/d orally, respectively. After 10 weeks, the levels of glycosylated hemoglobin (HbA1c), creatine phosphokinase isoenzyme (CK-MB), plasma brain natriuretic peptide (BNP), myocardial collagen volume fraction (CVF) and left ventricular mass index (LVWI) were measured. CK-MB levels in Ros-H and Ros-L rats were lower than in the diabetic group. Rosuvastatin alleviated myofibrosis cordis and fibroplastic proliferation. LVWI, BNP, CVF and TGF-beta1 mRNA and protein levels in the diabetic group were higher than in the control, but were reduced after rosuvastatin treatment. These results demonstrate that rosuvastatin dose-dependently reduces TGF-beta1 expression and inhibits the development of myocardial fibrosis in diabetic cardiomyopathy.
authors.affiliation: Department of Cardiology, First Affiliated Hospital of Xiamen University, China.
authors.forename: Yu-Xiao
authors.initials: YX
authors.lastname: Ma
authors.forename: Wei-Hua
authors.initials: WH
authors.lastname: Li
authors.forename: Qiang
authors.initials: Q
authors.lastname: Xie
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000473:pathology; D003094:Collagen / Q000378:metabolism; D003402:Creatine Kinase / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D058065:Diabetic Cardiomyopathies / Q000188:drug therapy* / Q000473:pathology; D005355:Fibrosis; D005464:Fluorobenzenes / Q000494:pharmacology*; D006442:Glycated Hemoglobin / Q000378:metabolism; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D017379:Hypertrophy, Left Ventricular / Q000473:pathology / Q000517:prevention & control; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D060888:Real-Time Polymerase Chain Reaction; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000494:pharmacology*; D053773:Transforming Growth Factor beta1 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis*
chemical_list: D003094:Collagen; D003402:Creatine Kinase; D005464:Fluorobenzenes; D006442:Glycated Hemoglobin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D020097:Natriuretic Peptide, Brain; D011743:Pyrimidines; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides; D053773:Transforming Growth Factor beta1